The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (15 analysts) rates it buy, with a mean price target of $88.
Alcon Inc ALC
Clears both ethical standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Alcon Inc.
read at $67.28
Alcon Inc holds its Markup at $67.28.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 20 days |
| Price | $67.28 |
| Valuation | 40.29 trailing · 16.96 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.70 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 9.40% |
| Profit margin | 7.70% |
| Debt to equity | 23.77 |
| Analyst consensus | Buy · 15 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
- Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
- Receivables Money owed to the company is of assets, above the 49% limit. Fail
- Revenue purity of revenue comes from non-compliant sources, over the 5% line. Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Eye care products at a quiet discount
Picture a patient in Zurich getting new lenses after cataract surgery or a teenager in Texas picking up monthly contacts. Both routes run through Alcon, the specialist supplier of surgical gear and vision care products that sits between big pharma and everyday opticians. The shares sit 25 percent below our fair value at a forward multiple of 17.7 times, with revenue climbing 9 percent and an ethical screen cleared.
Yet the numbers still do not add up to an opportunity. Return on equity is stuck at just 4 percent and the profit margin is only 8 percent, both modest for a business that carries only a narrow moat. Analyst targets cluster near 88 dollars, but the low returns and limited pricing power keep the name off our list despite the apparent discount.
Currency moves in emerging markets and steady competition from larger device makers remain real drags on margins. The setup looks stable rather than compelling.
Analysis, not advice.
| Forward P/E | 17.0x priced for continued growth |
| Trailing P/E | 40.3x expensive — the price assumes strong growth ahead |
| Revenue growth | 9.4% steady growth |
| Profit margin | 7.7% thin but positive margins |
| Return on equity | 3.7% a modest return on shareholder capital |
| Debt to equity | 0.24 minimal debt — a conservative balance sheet |
| Current ratio | 2.20 comfortably covers its short-term bills |
| Beta | 0.70 steadier than the market |
| Market cap | $32.8B |
| Employees | 25,000 |
The risks · The things to watch: its business and earnings are exposed to Switzerland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on ALC
- › Reasons to Retain Doximity Stock in Your Portfolio for Now Zacks · 16d ago
- › ISRG Q2 Earnings Beat Estimates, Stock Falls on Slow Procedure Growth Zacks · 16d ago
- › GMED Stock Surges 43.6% in a Year: What's Driving the Rally? Zacks · 16d ago
- › Will Declining Membership Affect Molina Healthcare's Q2 Earnings? Zacks · 16d ago
- › 3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles Zacks · 16d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in ALC's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (15 analysts) rates it buy, with a mean price target of $88.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 25%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (15 analysts) rates it buy, with a mean price target of $88.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The political ledger · congressional disclosures
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 7 May2026 | Sara Jacobs | Democrat | sell | 500K–1M |
| 6 May2026 | Sara Jacobs | Democrat | sell | 500K–1M |
| 2026-05-07 | Sara Jacobs | Democrat | Sale | 500K–1M |
| 2026-05-06 | Sara Jacobs | Democrat | Sale | 500K–1M |
| 2026-04-13 | Ro Khanna | Democrat | Sale | 1K–15K |
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $62.02 | +7.0% | · | $1,070 | +7.0% |
| 2 months | $77.63 | -14.5% | $0.36 | $859 | -14.1% |
| 3 months | $78.12 | -15.1% | $0.36 | $854 | -14.6% |
| 6 months | $78.38 | -15.3% | $0.36 | $851 | -14.9% |
| 1 year | $88.52 | -25.0% | $0.36 | $754 | -24.6% |
| 2 years | $90.68 | -26.8% | $0.69 | $739 | -26.1% |
| 3 years | $78.12 | -15.1% | $0.95 | $861 | -13.9% |
| 5 years | $69.21 | -4.1% | $1.39 | $979 | -2.1% |
Historical returns from market close data. Past performance does not guarantee future results.